SCHEMBL6525637

SCHEMBL6525637

COc1cccc(C(=O)Nc2ccc3c(=O)[nH]c4ncccc4c3c2)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.57
SMN1; SMN2 Q16637 5/20 0.55
TSHR P16473 3/20 0.55
KMT2A Q03164 5/20 0.54
MEN1 O00255 4/20 0.54
NPC1 O15118 7/20 0.54
RAB9A P51151 7/20 0.54
BRD4 O60885 1/20 0.53
BRPF1 P55201 1/20 0.53
RXFP1 Q9HBX9 1/20 0.53
TP53 P04637 3/20 0.53
KCNK3 O14649 1/20 0.53
KCNK9 Q9NPC2 1/20 0.53
KDM4E B2RXH2 1/20 0.53
NFKB1 P19838 1/20 0.53
NFKB2 Q00653 1/20 0.53
RELA Q04206 1/20 0.53
POLB P06746 2/20 0.53
MAPT P10636 1/20 0.53
OPRM1 P35372 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6521162 0.82 AURKA (0.55) KMT2AMEN1NPC1RAB9APOLB
SCHEMBL3454045 0.79 AURKA (0.54) KMT2AMEN1PKM
SCHEMBL6517544 0.78 FGFR1 (0.51) ALDH1A1SMN1; SMN2KMT2AMEN1NPC1
SCHEMBL2463981 0.78 KCNQ3 (0.56) ALDH1A1SMN1; SMN2TSHRKMT2AMEN1
SCHEMBL6519154 0.78 AURKA (0.55) ALDH1A1NPC1RAB9ABRD4KDM4E
SCHEMBL6517261 0.74 AURKA (0.54)
SCHEMBL3455031 0.74 PARP1 (0.56) KMT2AMEN1BRD4KDM4EPKM
SCHEMBL30862297 0.74 RXFP1 (0.94) ALDH1A1SMN1; SMN2TSHRKMT2AMEN1
SCHEMBL4251968 0.74 RXFP1 (0.94) ALDH1A1SMN1; SMN2TSHRKMT2AMEN1
SCHEMBL6521530 0.73 HIF1A (0.51) SMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8735584-B2 Protein kinase inhibitors and use thereof MERCK PATENT GMBH (DE) 2014-05-27 US disclosed
US-8735584-B2 Protein kinase inhibitors and use thereof MERCK PATENT GMBH (DE) 2014-05-27 US disclosed
US-8735584-B2 Protein kinase inhibitors and use thereof MERCK PATENT GMBH (DE) 2014-05-27 US disclosed
EP-2254889-B1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2012-12-19 EP disclosed
EP-2254889-B1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2012-12-19 EP disclosed
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2011-03-03 US disclosed
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2011-03-03 US disclosed
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2011-03-03 US disclosed
WO-2009108670-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK SERONO S.A. (CH) 2009-09-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MAP4K2, MAP3K20, MAP4K1 ALDH1A1 4501/4885SMN1; SMN2 3481/4885TSHR 2076/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.